Experimental Oncology, 2014, № 1

Grigoriy Vasilievich Bondar

Wed, 01 Jan 2014 00:00:00 GMT

Grigoriy Vasilievich Bondar Ukrainian oncology has suffered an irretrievable loss. Outstanding Ukrainian oncologist and surgeon, Hero of Ukraine, Honored Science and Technology Worker of Ukraine, general director of Donetsk Regional Anticancer Center, Head of the Chair of Oncology of Maxim Gorky Donetsk National Medical University, member of National Academy of Medical Sciences of Ukraine — Grigoriy Vasilievich Bondar died at the age of 81.

In search of molecular approaches to improving cancer therapy efficacy

Wed, 01 Jan 2014 00:00:00 GMT

In search of molecular approaches to improving cancer therapy efficacy Cherepenko, E.; Telegeev, G. The study of genome rearrangement sites using full genome sequences is an important approach to revealing the nature of cancer and finding effective ways for cancer treatment. The progress in DNA sequencing could make the procedure of whole genome reading close to routine procedure of lower cost. The personal analysis of rearranged ends (PARE) method used for rearrangement study is reviewed. PARE allows identifying of individual cancer biomarkers making personal medicine possible. Also, the progress in “liquid biopsy” technology based on detection of circulating tumor cells in the patient’s blood is shortly summarized. Another important approach is the discovered phenomenon of synthetic lethality causing cancer cell death due to appropriate combination of mutations in different genes or inhibitors of their protein products. Studies of genome rearrangements and synthetic lethality are considered promising for the development of effective cancer treatment approaches. Key Words: PARE, circulating tumor DNA, circulating tumor cells, liquid biopsy, synthetic lethality, cancer cell.

Biochip array technology and evaluation of serum levels of multiple cytokines and adhesion molecules in patients with newly diagnosed acute myeloid leukemia

Wed, 01 Jan 2014 00:00:00 GMT

Biochip array technology and evaluation of serum levels of multiple cytokines and adhesion molecules in patients with newly diagnosed acute myeloid leukemia Horacek, J.M.; Kupsa, T.; Vasatova, M.; Jebavy, L.; Zak, P. Aim: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia (AML) and in healthy subjects using biochip array technology. Methods: A total of 15 AML patients and 15 healthy subjects (blood donors) were studied. Serum samples were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. This approach allows multi-analytical determination from a single sample. T-tests were used for statistical analysis. Results: In newly diagnosed AML patients, we found significant increase (p < 0.01) in serum VCAM-1, ICAM-1, E-selectin, L-selectin, and significant increase (p < 0.05) in serum IL-6, IL-8. No significant differences were found in the levels of other evaluated cytokines and adhesion molecules. Conclusion: Our results indicate that serum levels of specific cytokines and adhesion molecules (VCAM-1, ICAM-1, E-selectin, L-selectin, IL-6, IL-8) are significantly altered in patients with newly diagnosed AML, showing activity of the disease. Whether these alterations could serve as a prognostic marker for AML is not known. Further studies will be needed to define the potential role of these and additional markers in the risk stratification of AML. Key Words: cytokines, adhesion molecules, biochip array, acute myeloid leukemia.

Anticancer efficacy of hydroxyethylthiamine diphosphate in vivo

Wed, 01 Jan 2014 00:00:00 GMT

Anticancer efficacy of hydroxyethylthiamine diphosphate in vivo Gevorkyan, L.; Gambashidze, K. Aim: The aim of the presented article was investigation of anticancer efficacy of hydroxyethylthiamine diphosphate (HTD) in vivo. Materials and Methods: The study was carried out on 30 C57BL/6J mice subcutaneously transplanted with Ehrlich carcinoma. Animals were treated with intraperitoneal injections of the solution composed from pyruvic acid and thiamine bromide every other day during 10 days and thereafter, every day during 2 weeks. Treatment efficacy was evaluated by tumor growth inhibition. Results: In experimental animals treated with HTD, significant tumor growth inhibition has been registered: 73% at day 45th compared to the control group (p < 0.001). Conclusion: Treatment with HTD demonstrated high anticancer efficacy in vivo. Key Words: carcinogenesis, pH, hydroxyethylthiamine diphosphate, lipoic acid amide.